Amgen’s investigational monoclonal antibody paired with chemotherapy significantly improved overall survival for patients in ...

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab in combination with ...

M.D., executive vice president of Research and Development at Amgen. "These first positive top-line results of an FGFR2b targeted monoclonal antibody from our Phase 3 FORTITUDE-101 study mark a ...

Amgen acquired Five Prime in 2021 on the back of the phase 2 FIGHT trial of bemarituzumab, which achieved significant ...

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

Amgen said on Monday its experimental therapy helped patients with advanced gastric cancer live longer when combined with ...

Amgen announced the phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) ... (G/GEJ) cancer with FGFR2b overexpression and who are non-HER2 positive.

In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though ...

Amgen’s targeted antibody is designed to block the activation of FGFR2b, inhibiting several signaling pathways with the goal of potentially slowing cancer progression. 17 ...

amgen announces positive topline phase 3 results for bemarituzumab in fibroblast growth factor receptor 2b (fgfr2b) positive first-line gastric cancer Jun. 30, 2025 9:00 AM ET Amgen Inc. (AMGN) ...

amgen announces positive topline phase 3 results for bemarituzumab in fibroblast growth factor receptor 2b (fgfr2b) positive first-line gastric cancer Provided by PR Newswire Jun 30, 2025, 1:00:00 PM ...